Peptide basics
Peptides are chains of amino acids. Their sequence helps determine how they interact with other molecules.
PEPTIDE RESEARCH & EDUCATION
A starting point for understanding peptides, reading study results and asking better questions about the evidence.
Explore the research guide
RESEARCH GUIDE
Peptides are chains of amino acids. Their sequence helps determine how they interact with other molecules.
Start with who took part, what the researchers measured and what they used for comparison. Those details shape what the results can tell you.
Check whether a headline reports a group average, a result for one subgroup or an individual outcome. Look for how long the study followed participants.
Retatrutide is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. Researchers have studied it in randomised, placebo-controlled trials in adults.
The trial enrolled 338 adults. At 48 weeks, the highest-dose group had an estimated average weight reduction of 24.2%, compared with 2.1% in the placebo group. The trial’s primary endpoint was measured at 24 weeks.
This trial compared retatrutide with placebo in adults with obesity without diabetes over 80 weeks. When reading the findings, look at the weight outcomes alongside adverse events and how many participants stopped treatment.
Read the full retatrutide research guide and FAQs
Medsafe warns that unapproved peptide products may have unknown ingredients, strength or sterility. Read Medsafe’s November 2026 safety alert.
FAQ
Read the abstract for the research question, then check the methods and limitations. The methods explain who took part, how the study was run and how the outcomes were measured.
They may enrol different participants, use different comparison groups or track outcomes over different periods. Compare those details before putting the numbers side by side.
Peer review means other specialists assessed the paper before publication. It is still worth checking the study design, funding and whether other researchers have found similar results.
Phase 2 trials typically provide an early look at effects and side effects in the target population. Phase 3 trials generally enrol more people to test outcomes and collect more safety data.
Individual outcomes vary. The 24.2% figure is an estimated group average at 48 weeks in one arm of a Phase 2 trial. Check which participants were studied and compare the result with the placebo group.
Medsafe identifies retatrutide as investigational and warns about unapproved peptide products. Trial results are one part of the evidence regulators consider when assessing a medicine. Read Medsafe’s retatrutide advisory.